The Human Experience with Intravenous Levodopa

Frontiers in Pharmacology
Shan H SiddiqiKevin J Black

Abstract

To compile a comprehensive summary of published human experience with levodopa given intravenously, with a focus on information required by regulatory agencies. While safe intravenous (IV) use of levodopa has been documented for over 50 years, regulatory supervision for pharmaceuticals given by a route other than that approved by the U.S. Food and Drug Administration (FDA) has become increasingly cautious. If delivering a drug by an alternate route raises the risk of adverse events, an investigational new drug (IND) application is required, including a comprehensive review of toxicity data. Over 200 articles referring to IV levodopa were examined for details of administration, pharmacokinetics, benefit, and side effects. We identified 142 original reports describing IVLD use in humans, beginning with psychiatric research in 1959-1960 before the development of peripheral decarboxylase inhibitors. At least 2760 subjects have received IV levodopa, and reported outcomes include parkinsonian signs, sleep variables, hormone levels, hemodynamics, CSF amino acid composition, regional cerebral blood flow, cognition, perception and complex behavior. Mean pharmacokinetic variables were summarized for 49 healthy subjects and 190 with Parki...Continue Reading

Associated Clinical Trials

Jul 2, 2017·Kevin J. Black, MD

References

May 1, 1977·Acta diabetologica latina·G GragnoliG Migliarese
Jan 1, 1992·Movement Disorders : Official Journal of the Movement Disorder Society·F StocchiA Agnoli
Jan 1, 1991·Journal of Neural Transmission. General Section·P HartvigB Långström
Jan 1, 1990·European Journal of Clinical Pharmacology·E BredbergL Paalzow
Jul 1, 1989·British Journal of Clinical Pharmacology·D R RobertsonC F George
Jan 1, 1987·Journal of Neural Transmission·A BraunT N Chase
Jan 1, 1988·European Journal of Clinical Pharmacology·D WorthM Lee
Jan 1, 1988·Movement Disorders : Official Journal of the Movement Disorder Society·S RuggieriA Agnoli
Oct 1, 1987·Annals of Neurology·M M MouradianT N Chase
Aug 1, 1987·Clinical Neuropharmacology·M M MouradianT N Chase
Jul 1, 1987·Neurology·J L JuncosT N Chase
Jul 1, 1987·Journal of Neurology, Neurosurgery, and Psychiatry·M J JaffeD R Weinberger
Aug 1, 1973·Electroencephalography and Clinical Neurophysiology·J C GillinW E Bunney
Aug 8, 1967·Archiv für Psychiatrie und Nervenkrankheiten·W Birkmayer, M Mentasti
Jan 1, 1973·Journal of Neural Transmission·W BirkmayerP Riederer
Jun 1, 1973·Acta Endocrinologica·A SouvatzoglouP Bottermann
Jan 1, 1968·European Neurology·U K Rinne, V Sonninen
Oct 29, 1965·Deutsche medizinische Wochenschrift·W Umbach, O Tzavellas
Jan 1, 1966·Acta Neurologica Scandinavica·C Fehling
Feb 16, 1967·The New England Journal of Medicine·G C CotziasL M Schiffer
Jan 1, 1966·Acta Psychiatrica Scandinavica·A Bruno, S C Bruno
Oct 29, 1965·Deutsche medizinische Wochenschrift·E Metzel
Jun 15, 1966·Klinische Wochenschrift·N MatussekE Rüther
Mar 17, 1967·Deutsche medizinische Wochenschrift·K Aebert

❮ Previous
Next ❯

Citations

Jun 2, 2020·Frontiers in Neurology·Kevin J BlackJonathan M Koller
May 25, 2021·Biochemistry and Biophysics Reports·Aminu UsmanBrendan S Wilhelmi
Oct 23, 2020·Pharmacology, Biochemistry, and Behavior·Tanvi Pingale, Girdhari Lal Gupta

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
sedation

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here